Xencor, Inc. (XNCR)

23,66 -0,58 (-2,39%) Alla chiusura: 04:00PM EDT

Xencor, Inc.

465 North Halstead Street
Suite 200
Pasadena, CA 91107
United States
626 305 5900
https://www.xencor.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 280

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Bassil I. Dahiyat Ph.D.	Co-Founder, CEO, President & Director	1,07M	2,3M	1970
Dr. John R. Desjarlais Ph.D.	Executive VP of Research & Chief Scientific Officer	748,65k	N/D	1964
Ms. Celia E. Eckert J.D.	Senior VP, General Counsel & Corporate Secretary	641,85k	N/D	1973
Dr. Nancy Valente M.D.	Executive VP & Chief Development Officer	797,68k	N/D	1959
Mr. Bart Jan Cornelissen	Senior VP & CFO	N/D	N/D	N/D
Mr. Charles Liles	Associate Director and Head of Corporate Communications & Investor Relations	N/D	N/D	N/D
Ms. Jennifer Sandoz	Senior VIce President of Human Resources	N/D	N/D	N/D
Dr. Jeremy Grunstein Ph.D.	Senior Vice President of Business Development	N/D	N/D	N/D
Mr. Kirk Rosemark RAC	Senior Vice President of Regulatory Affairs & Quality Assurance	N/D	N/D	1965
Mr. Eric P. Kowack	Senior Vice President of Program Leadership & Alliance Management	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

Governance aziendale

L'ISS Governance QualityScore di Xencor, Inc. al 1 maggio 2024 è 6. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 6; diritti degli azionisti: 4; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.